22 December 2025
Watkin Jones plc (‘Watkin Jones’ or the ‘Group’) Development Partnership for 294-unit hotel in Wimbledon Watkin Jones, the UK’s leading developer and manager of…
LONDONMETRIC PROPERTY PLC LONDONMETRIC TRANSACTS ON £91 MILLION OF INVESTMENT ACTIVITY LondonMetric Property Plc (“LondonMetric”) announces that it has sold £64.4 million of retail assets…
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans GSK plc (LSE/NYSE: GSK)…
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Tenth Breakthrough Therapy Designation for AstraZeneca and…
Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer The LATIFY Phase III trial of ceralasertib in…
17 December 2025
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma · Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients…
16 December 2025
16 December 2025 Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus Convenient subcutaneous option has potential to reach…
16 December 2025 Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive…